HPV16Z-Hsp65-E6／E7无佐剂重组蛋白疫苗的研究  

Study of therapeutic adjuvant-free protein vaccine-HPV16Z-Hsp65-E6/E7

作　　者：王小兵[1] 李茉[1] 刘朝阳[1] 田海梅[1] 曲平[1] 李艳芬[1] 刘毅[1] 曹冬艳[1] 粱智 程冬婉[1] 邵长君[1] 张伟[1] 

机构地区：[1]中国协和医科大学中国医学科学院肿瘤研究所生物检测中心,北京100021

出　　处：《中国肿瘤生物治疗杂志》2006年第1期8-12,共5页Chinese Journal of Cancer Biotherapy

摘　　要：目的:研究治疗性HPV16Z-Hsp65-E6／E7无佐剂重组蛋白疫苗的抗肿瘤活性。方法:通过淋巴细胞增殖实验和细胞毒性杀伤实验研究该疫苗激发的细胞免疫反应及反应强度;观察该疫苗对小鼠TC-1肿瘤细胞移植瘤的体内治疗作用和对小鼠生存期的影响。结果:重组蛋白疫苗免疫小鼠后,小鼠脾淋巴细胞与该疫苗体外混合培养增殖明显,并可特异性地在体外杀伤TC-1细胞;体内抑瘤试验显示该疫苗对HPV16病毒转化的TC-1细胞小鼠移植瘤的生长有显著的抑制作用。结论:该疫苗能激发特异性细胞免疫反应;显著抑制HPV16转化的TC-1肿瘤细胞生长。Objective： To study the biological effects of the HPV16Z-Hsp65-E6/E7 fusion protein vaccine on the tumor associated with HPV16 infection. Methods ： We tested the cellular immune responsive intensity to the vaccine by the lymphocyte proliferation and CTL response, and studied the therapeutic effect of the vaccine on mouse TC-1 cell transplanted cancer in vivo and the influence on mouse lifetime. Results： The spleen lymphocytes from the C57BL/6 mouse immunized by the Hsp65-E6/E7 vaccine could proliferate obviously in the presence of the protein and TC-1 tumor cell could be lysed specifically by immune activated lymphocytes in vitro. This animal therapeutic experiment in vivo showed that the vaccine suppressed the growth of TC-1 cell transplanted tumor remarkably. Conclusion ： The recombined vaccine can induce specific cellular immune response in vitro and suppress HPV16 positive TC-1 tumor cell growth obviously in vivo.

关 键 词：人乳头瘤病毒16型 治疗性疫苗 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]